Deutsche Bank AG purchased a new stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 976,612 shares of the biotechnology company's stock, valued at approximately $8,174,000. Deutsche Bank AG owned approximately 0.42% of ADMA Biologics as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently modified their holdings of the company. State Street Corp grew its holdings in shares of ADMA Biologics by 0.3% in the 4th quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company's stock worth $248,014,000 after acquiring an additional 35,614 shares during the last quarter. Sachem Head Capital Management LP lifted its holdings in shares of ADMA Biologics by 27.0% during the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company's stock valued at $207,480,000 after purchasing an additional 2,415,000 shares during the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of ADMA Biologics by 36.9% during the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company's stock valued at $127,551,000 after purchasing an additional 1,886,105 shares during the last quarter. Capital Research Global Investors lifted its holdings in shares of ADMA Biologics by 104.0% during the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company's stock valued at $121,067,000 after purchasing an additional 3,383,559 shares during the last quarter. Finally, Nuveen LLC boosted its position in shares of ADMA Biologics by 3.5% in the 4th quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company's stock valued at $108,097,000 after purchasing an additional 202,245 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.
ADMA Biologics Stock Performance
Shares of ADMA stock opened at $9.84 on Monday. ADMA Biologics Inc has a 1-year low of $7.21 and a 1-year high of $20.46. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $2.20 billion, a price-to-earnings ratio of 14.06 and a beta of 0.74. The stock's fifty day simple moving average is $8.96 and its 200-day simple moving average is $10.75.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The firm had revenue of $124.39 million during the quarter, compared to the consensus estimate of $125.34 million. During the same period in the prior year, the business earned $0.14 EPS. The business's revenue for the quarter was up 2.0% on a year-over-year basis. On average, sell-side analysts predict that ADMA Biologics Inc will post 0.78 earnings per share for the current fiscal year.
Analyst Ratings Changes
ADMA has been the topic of several recent analyst reports. Canaccord Genuity Group cut their price objective on ADMA Biologics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, May 7th. Mizuho decreased their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating for the company in a report on Wednesday, July 15th. Wall Street Zen downgraded shares of ADMA Biologics from a "buy" rating to a "hold" rating in a research report on Monday, May 4th. Raymond James Financial initiated coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They issued an "outperform" rating and a $21.00 target price on the stock. Finally, Weiss Ratings restated a "hold (c)" rating on shares of ADMA Biologics in a report on Thursday, June 18th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $18.67.
Get Our Latest Report on ADMA
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.
Featured Articles
Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
